WDR35 Is Associated with Chemosensitivity and Prognosis in Lung Adenocarcinoma
Cancer Biotherapy and Radiopharmaceuticals · 2025
DOI: 10.1089/cbr.2025.0124 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Biotherapy and Radiopharmaceuticals, 2025. Verfasst von Liang Tang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Surgery, Dazhou Central Hospital, Dazhou, China. Hauptthemen laut MEDLINE: Adenocarcinoma of Lung, Lung Neoplasms, Drug Resistance, Neoplasm, Biomarkers, Tumor. Die Arbeit nennt 29 Literaturangaben.
Abstract (Originalsprache)
Background
This study investigated the expression characteristics of WD repeat domain 35 (WDR35) in lung adenocarcinoma (LUAD) and its association with chemotherapy sensitivity and prognosis.
Methods
Differentially expressed genes were analyzed in combination with Random Forest and Support Vector Machine algorithms to identify key genes associated with chemotherapy sensitivity. The expression differences of the core gene at both transcriptomic and proteomic levels were then experimentally validated using real-world LUAD samples. Drug sensitivity analysis was conducted using the Genomics of Drug Sensitivity in Cancer database to evaluate the correlation between the core gene and the IC50 values of various chemotherapeutic agents. Gene Set Enrichment Analysis (GSEA) was used to explore the potential mechanisms involved. Finally, Kaplan-Meier survival analysis and stratified analysis by tumor stage and lymph node status were performed to assess the prognostic value of the core gene.
Results
WDR35 as a core gene associated with chemotherapy sensitivity and highly expressed in normal lung tissue compared with tumor tissue, which was further validated at both the qPCR and proteomic levels. Clinical correlation analysis indicated that WDR35 expression is significantly associated with tumor size, lymph node metastasis, and tumor stage. Further analysis revealed that patients with high WDR35 expression were more likely to achieve partial or complete response to initial chemotherapy. Drug sensitivity prediction analysis demonstrated that high WDR35 expression was significantly correlated with increased sensitivity to various anticancer drugs. GSEA pathway enrichment analysis suggested that WDR35 may enhance chemotherapy sensitivity by regulating stress response and metabolic pathways. Survival analysis indicated that high WDR35 expression was associated with better overall survival and disease-specific survival.
Conclusions
Our study reveals that WDR35 is closely associated with chemotherapy sensitivity and prognosis in lung adenocarcinoma.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Thoracic Surgery, Dazhou Central Hospital, Dazhou, China.
- Department of Thoracic Surgery, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China.
- Department of Thyroid and Breast Surgery, Dazhou Central Hospital, Dazhou, China.
- Department of Medicine II, University Hospital, LMU Munich, Munich, Germany.
ORCID-Profile: Youshan Li
Zitieren
APA
Tang, L., Xu, Y., Zhang, X., Song, T., Wei, Y., Zhang, H., Zhou, Y., & Li, Y. (2025). WDR35 Is Associated with Chemosensitivity and Prognosis in Lung Adenocarcinoma. Cancer Biotherapy and Radiopharmaceuticals. https://doi.org/10.1089/cbr.2025.0124
Vancouver
Tang L, Xu Y, Zhang X, Song T, Wei Y, Zhang H, et al. WDR35 Is Associated with Chemosensitivity and Prognosis in Lung Adenocarcinoma. Cancer Biotherapy and Radiopharmaceuticals. 2025. doi:10.1089/cbr.2025.0124
BibTeX
@article{Tang2025,
author = {Tang, Liang and Xu, Yinhui and Zhang, Xinmiao and Song, Tianjun and Wei, Yirui and Zhang, Haijun and Zhou, Yunfei and Li, Youshan},
title = {WDR35 Is Associated with Chemosensitivity and Prognosis in Lung Adenocarcinoma},
journal = {Cancer Biotherapy and Radiopharmaceuticals},
year = {2025},
doi = {10.1089/cbr.2025.0124}
}
EUVIMED